A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers after their primary treatment, and was published in the journal Neuro-Oncology in 2024.

Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases. In some patients, the disease returns or progresses within six months of the last platinum dose,

Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 doseFLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences,

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib

Fred Hutch Cancer Center researchers are seeking better ways to prevent, detect and treat bladder cancer. We are also working to better understand the factors that affect each person’s risk for this cancer. Our scientists are also developing new methods ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S.

A phase 3 global trial is enrolling previously treated locally advanced/metastatic nonsquamous NSCLC to define DATROWAY efficacy and safety at scale. IDE034 is in open-label phase 1 dose-escalation/expansion across advanced solid tumors, including NSCLC ...

Despite the many benefits of clinical trials, misconceptions still exist. Get the facts, so you can make an informed choice about whether applying for a trial is right for you. Whether you are at the start of the cancer journey or have been navigating your ...

LSU Health Shreveport is offering free head and neck cancer screenings this month while leading national clinical trials aimed at improving cancer treatment, officials said.The screenings will

SUCCEED trial enables remote participation for small cell lung cancer patients, addressing location barriers and enhancing research opportunities. NXP800 shows promise in recurrent, platinum-resistant ovarian cancer, but development will shift focus to ...